Impact of Continuous Estroprogestin Treatment on Circulating Microparticle Levels in Deep Endometriosis Patients

There has been increasing interest in the study of new pathogenic mechanisms in endometriosis (END), including the coagulation/fibrinolysis system and its link with inflammation and tissue remodeling. It has been suggested that END patients, especially with deep-infiltrating (DE) forms, could present a hypercoagulable state revealing higher levels of proinflammatory and procoagulant markers, such as total circulating microparticles (cMPs) and cMP-TF (tissue factor), released by cells in response to damage, activation, or apoptosis. However, no previous study has assessed the effect of END hormonal treatments on cMP and cMP-TF levels. Therefore, the aim of this study was to evaluate the impact of these treatments on cMP and cMP-TF levels in DE patients. Three groups were compared: DE patients receiving a continuous combined oral contraceptive regimen (CCOCR) (n = 41), DE patients without CCOCR (n = 45), and a control group (n = 43). cMP and cMP-TF levels were evaluated in platelet-free plasma. A significant decrease in the total cMP levels was found in the DE group with CCOCR versus the group without CCOCR, reflecting a higher chronic inflammatory status in DE patients that decreased with the treatment. cMP-TF levels were higher in DE patients receiving CCOCR versus those not receiving CCOCR, suggesting that treatments containing estrogens play a predominant role in suppressing the inhibitory pathway of TF.

Automated summary

There is increasing interest in studying the pathogenic mechanisms of endometriosis, especially in relation to the coagulation/fibrinolysis system and its connection with inflammation and tissue remodeling. This study aimed to evaluate the impact of hormonal treatments on microparticle levels in deep-infiltrating endometriosis (DE) patients. The results showed that DE patients receiving a continuous combined oral contraceptive regimen (CCOCR) had lower levels of total circulating microparticles (cMPs), indicating a decrease in chronic inflammation. However, cMP-TF levels were higher in DE patients receiving CCOCR, suggesting a suppression of the inhibitory pathway of tissue factor (TF) by estrogen-containing treatments.